INSMED: Peers

The FY2023 (Dec) proxy of INSMED names 14 peer companies for pay. Pay versus performance data of INSMED for that year is not on file, so it has no rank.

Pay peer group, FY2023 (Dec) proxy

Acadia Pharmaceuticals Inc.Not disclosedNot disclosed
Agios Pharmaceuticals, Inc.Not disclosedNot disclosed
Amicus Therapeutics, Inc.Not disclosedNot disclosed
Arrowhead PharmaceuticalsNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
Corcept Therapeutics IncorporatedNot disclosedNot disclosed
Editas Medicine, Inc.Not disclosedNot disclosed
Halozyme Therapeutics, Inc.Not disclosedNot disclosed
Intercept Pharmaceuticals, Inc.Not disclosedNot disclosed
Nektar TherapeuticsNot disclosedNot disclosed
PTC Therapeutics, Inc.Not disclosedNot disclosed
Sangamo Therapeutics, Inc.Not disclosedNot disclosed
Sarepta Therapeutics, Inc.Not disclosedNot disclosed
Ultragenyx Pharmaceutical Inc.Not disclosedNot disclosed
14 companies

Changes by year

FY2024 (Dec) proxy

  • RemovedEditas Medicinepay peer groupgiven their relative size and performance
  • RemovedNektar Therapeuticspay peer groupgiven their relative size and performance

FY2023 (Dec) proxy

  • RemovedAcceleronpay peer groupfollowing completion of Merck’s acquisition of Acceleron in 2021
  • RemovedAcceleron Pharma Inc.pay peer groupfollowing completion of Merck’s acquisition of Acceleron in 2021
  • RemovedClovis Oncology, Inc.pay peer groupfollowing completion of Merck’s acquisition of Acceleron in 2021
  • RemovedHeron Therapeuticspay peer groupfollowing completion of Merck’s acquisition of Acceleron in 2021
  • RemovedOmeros Corporationpay peer groupfollowing completion of Merck’s acquisition of Acceleron in 2021

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.